Financial Results for the year ended 31st March 2026.

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults RestatedResults View source PDF

SUDEEPPHRM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+4.7%1-day move

₹665.00

prior close

₹656.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-1.7-1.3-1.2-0.2+4.7+4.7+1.5+11.6+16.8+15.2+23.2+24.7+27.1—

Up moveDown movePending

AI summary

Sudeep Pharma reported strong FY26 results with consolidated revenue growing 28% to Rs. 64,226 lakhs from Rs. 50,200 lakhs. Profit after tax rose 26% to Rs. 17,428 lakhs from Rs. 13,873 lakhs. EPS stands at Rs. 15.50. The company completed its IPO in November 2025 raising Rs. 9,500 lakhs and acquired Nutrition Supplier & Services (Ireland) Limited as a step-down subsidiary for Rs. 12,858 lakhs. The Board recommended a final dividend of Rs. 1.50 per share. The company operates in two segments: Pharmaceutical/Food/Nutrition and Speciality Ingredients.

Likely market impact

Strong financial performance with 26% PAT growth and 28% revenue growth indicates solid operational execution. The recent IPO and international acquisition expand the company's scale and global footprint, which could be positive for shareholders.